MB
CNTX icon

MPM BioImpact’s Context Therapeutics CNTX Stock Holding History

MPM BioImpact’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$720K Sell
1,299,046
-9,380,345
-88% -$19M 0.04% 36
2026
Q1 		$28M Hold
10,679,391
– – 2.16% 18
2025
Q4 		$15.7M Sell
10,679,391
-4,026,491
-27% -$4.7M 1.8% 26
2025
Q3 		$14.2M Hold
14,705,882
– – 2.33% 20
2025
Q2 		$9.64M Hold
14,705,882
– – 1.67% 28
2025
Q1 		$9M Hold
14,705,882
– – 1.55% 30
2024
Q4 		$15.4M Buy
+14,705,882
New +$25.4M 2.19% 18

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

MPM BioImpact's CNTX Position: Q2 2026 in Review

MPM BioImpact reduced its Context Therapeutics (CNTX) stake by 88% in Q2 2026, selling an estimated $19M and leaving 1,299,046 shares worth $720K. The position accounts for 0.04% of the portfolio, ranked #36.

MPM BioImpact first reported a position in CNTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $28M in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • MPM BioImpact held 1,299,046 shares of Context Therapeutics worth $720K as of Q2 2026.
  • MPM BioImpact sold 9,380,345 Context Therapeutics shares in Q2 2026, an estimated $19M.
  • Context Therapeutics made up 0.04% of MPM BioImpact's portfolio in Q2 2026, its #36 holding.
  • MPM BioImpact first reported a position in Context Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • MPM BioImpact's Context Therapeutics position peaked at $28M in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.